Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study

Digestive and Liver Disease

Volumn 37, Issue 8, 2005, Pages 577-583

  Orlando, A ^a   Colombo, E ^b   Kohn, A ^c   Biancone, L ^d   Rizzello, F ^e   Viscido, A ^f   Sostegni, R ^g   Benazzato, L ^h   Castiglione, F ⁱ   Papi, C ^j   Meucci, G ^k   Riegler, G ^l   Mocciaro, F ^m   Cassinotti, A ^b   Cosintino, R ^c   Geremia, A ^d   Morselli, C ^e   Angelucci, E ^f   Lavagna, A ^g   Rispo, A ⁱ   Bossa, F ^l   Scimeca, D ^m   Cottone, M ^a   more..

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f POLICLINICO UMBERTO I   (Italy)

^g MAURIZIANO HOSPITAL   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j SAN FILIPPO NERI HOSPITAL   (Italy)

^k VALDUCE HOSPITAL   (Italy)

^l SECOND UNIVERSITY OF NAPLES   (Italy)

^m UNIVERSITY OF PALERMO   (Italy)

more..

Author keywords

Crohn's disease; Infliximab; Predictors of response

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; THALIDOMIDE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL SURGERY; ABSCESS; ABSCESS DRAINAGE; ADULT; AGE; ANGIONEUROTIC EDEMA; ANUS CARCINOMA; ANUS FISTULA; ARTICLE; BILE DUCT CARCINOMA; BREAST ADENOCARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; FEMALE; HEALTH CARE FACILITY; HUMAN; INTESTINE FISTULA; INTESTINE OBSTRUCTION; ITALY; LARYNX CARCINOMA; LEUKEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYALGIA; MYCOSIS; PATIENT REFERRAL; PREDICTION; REMISSION; SEX DIFFERENCE; SKIN CARCINOMA; SMOKING HABIT; TREATMENT OUTCOME; FISTULA; SMOKING;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FISTULA; GASTROINTESTINAL AGENTS; HUMANS; ITALY; MALE; MULTIVARIATE ANALYSIS; REMISSION INDUCTION; SMOKING;

EID: 26444478543     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.01.019     Document Type: Article

References (18)

1. Van Deventer S.J. Tumor necrosis factor and Crohn's disease. Gut 40 (1997) 443-448
2. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
3. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
4. Cohen R.D., Tsang J.F., and Hanauer S.B. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 95 (2000) 3469-3477
5. Ardizzone S., Colombo E., Maconi G., Bollani S., Manzionna G., Petrone M.C., et al. Infliximab in the treatment of Crohn's disease: the Milan experience. Dig Liver Dis 34 (2002) 411-418
6. Farrell R.J., Shah S.A., Lodhavia P.J., Alsahli M., Falchuk K.R., Michetti P., et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 95 (2000) 3490-3497
7. Ricart E., Panaccione R., Loftus E.V., Tremaine W.J., and Sandborn W.J. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96 (2001) 722-729
8. Sample C., Bailey R.J., Todoruk D., Sadowski D., Gramlich L., Milan M., et al. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. Can J Gastroenterol 16 (2002) 165-170
9. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
10. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
11. Remicade (infliximab). Centocor Inc.; 2000.
12. Cottone M., Orlando A., Casà A., and Oliva L. Maintenance infliximab for Crohn's disease. Lancet 360 (2002) 1602
13. Fefferman D.S., Lodhavia P.J., Alsahli M., Falchuk K.R., Peppercorn M.A., Shah S.A., et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis 10 (2004) 346-351
14. Vermeire S., Louis E., Carbonez A., Van Assche G., Noman M., Belaiche J., et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 97 (2002) 2357-2363
15. Parsi M.A., Achkar J.P., Richardson S., Katz J., Hammel J.P., Lashner B.A., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123 (2002) 707-713
16. Cottone M., Rosselli M., Orlando A., Oliva L., Puleo A., Cappello M., et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 106 (1994) 265-272
17. Parsi M.A., Lashner B.A., Achkar J., Connor J.T., and Brzezinski A. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease. Am J Gastroenterol 99 (2004) 445-449
18. Ardizzone S., Maconi G., Colombo E., Manzionna G., Bollani S., and Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcomes. Inflamm Bowel Dis 10 (2004) 91-96